Bellevue Group’s MacroGenics MGNX Stock Holding History

Bellevue Group’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,919,992	Closed	-$16.7M	–	183
2025 Q3	$16.7M	Hold	9,919,992	–	–	0.35%	50
2025 Q2	$12M	Sell	9,919,992 -9,971	-0.1%	-$14.5K	0.26%	61
2025 Q1	$12.6M	Hold	9,929,963	–	–	0.28%	65
2024 Q4	$32.3M	Hold	9,929,963	–	–	0.62%	38
2024 Q3	$32.7M	Sell	9,929,963 -12,350	-0.1%	-$48.1K	0.53%	58
2024 Q2	$42.3M	Sell	9,942,313 -23,549	-0.2%	-$229K	0.69%	36
2024 Q1	$147M	Buy	9,965,862 +12,549	+0.1%	+$190K	2.24%	13
2023 Q4	$95.8M	Buy	9,953,313 +150,000	+2%	+$1.04M	1.46%	18
2023 Q3	$45.7M	Buy	9,803,313 +193,400	+2%	+$963K	0.74%	38
2023 Q2	$51.4M	Hold	9,609,913	–	–	0.73%	42
2023 Q1	$68.9M	Buy	9,609,913 +630,000	+7%	+$3.79M	1%	34
2022 Q4	$60.3M	Buy	8,979,913 +1,654,399	+23%	+$9.07M	0.8%	39
2022 Q3	$25.3M	Hold	7,325,514	–	–	0.36%	73
2022 Q2	$21.6M	Hold	7,325,514	–	–	0.31%	83
2022 Q1	$64.5M	Sell	7,325,514 -1,234,948	-14%	-$13.6M	0.75%	44
2021 Q4	$137M	Buy	8,560,462 +15,865	+0.2%	+$299K	1.42%	19
2021 Q3	$179M	Buy	8,544,597 +1,168,571	+16%	+$28.1M	1.82%	12
2021 Q2	$198M	Buy	7,376,026 +1,348,100	+22%	+$39.5M	1.93%	10
2021 Q1	$192M	Buy	6,027,926 +123,409	+2%	+$3M	2.03%	10
2020 Q4	$135M	Buy	5,904,517 +622,329	+12%	+$14.3M	1.55%	18
2020 Q3	$133M	Buy	5,282,188 +280,072	+6%	+$7.65M	1.84%	14
2020 Q2	$140M	Sell	5,002,116 -1,117,034	-18%	-$19.4M	1.98%	12
2020 Q1	$35.6M	Buy	6,119,150 +245,794	+4%	+$2.23M	0.69%	40
2019 Q4	$63.9M	Buy	5,873,356 +747,792	+15%	+$7.4M	1.01%	32
2019 Q3	$65.4M	Buy	5,125,564 +730,300	+17%	+$10.5M	1.22%	23
2019 Q2	$74.6M	Buy	4,395,264 +3,604,959	+456%	+$61.9M	1.27%	23
2019 Q1	$14.2M	Sell	790,305 -276,688	-26%	-$4.78M	0.78%	44
2018 Q4	$13.6M	Buy	1,066,993 +342,691	+47%	+$5.75M	0.89%	34
2018 Q3	$15.5M	Buy	724,302 +127,389	+21%	+$2.72M	0.99%	33
2018 Q2	$12.3M	Buy	596,913 +33,762	+6%	+$760K	1.05%	34
2018 Q1	$14.2M	Sell	563,151 -1,250	-0.2%	-$30.4K	1.4%	23
2017 Q4	$10.7M	Buy	564,401 +131,102	+30%	+$2.45M	1.12%	35
2017 Q3	$8.01M	Buy	433,299 +116,881	+37%	+$2.02M	0.84%	43
2017 Q2	$5.54M	Buy	316,418 +11,821	+4%	+$225K	0.66%	56
2017 Q1	$5.67M	Buy	304,597 +221,597	+267%	+$4.27M	0.76%	47
2016 Q4	$1.7M	Hold	83,000	–	–	0.35%	70
2016 Q3	$2.48M	Hold	83,000	–	–	0.45%	62
2016 Q2	$2.24M	Hold	83,000	–	–	0.42%	68
2016 Q1	$1.56M	Buy	+83,000	New	+$1.58M	0.28%	85

Other funds holding MGNX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bellevue Group's MGNX Position: Q4 2025 in Review

Bellevue Group sold out of MacroGenics (MGNX) in Q4 2025, closing a stake of 9,919,992 shares — an estimated $16.7M sold.

Bellevue Group first reported a position in MGNX in Q1 2016 and held it in 39 quarters. The position peaked at $198M in Q2 2021. 88 funds tracked by Wall St. Rank hold MGNX as of Q4 2025.

Bellevue Group reported no remaining MacroGenics position as of Q4 2025 after selling out during the quarter.
Bellevue Group sold 9,919,992 MacroGenics shares in Q4 2025, an estimated $16.7M.
Bellevue Group first reported a position in MacroGenics in Q1 2016 and held it in 39 quarters.
Bellevue Group's MacroGenics position peaked at $198M in Q2 2021.
88 funds tracked by Wall St. Rank held MacroGenics as of Q4 2025.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.